Medis

Name

Medis

Legal name

Medis, d.o.o.

Website

https://medis.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Commercialization Services

SIC

Services-Health Services (8000)

akta.pro primary industry

Healthcare/Pharma Creative Agencies (MPAAAAAJ)

Keywords

• Pharmaceutical commercialization
• Specialty pharmaceuticals
• Orphan drugs
• Market access services
• Regulatory affairs

Headquarters

HQ city

Crnuce

HQ country

Slovenia

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Commercialization Services: Medis earns fees and revenue by commercializing innovative specialty pharmaceuticals, orphan drugs, medical technologies, and consumer health products on behalf of pharmaceutical and biotech companies seeking growth in Central & Eastern Europe and Greece. Services include regulatory affairs, pharmacovigilance, market access, marketing, sales, supply chain, quality assurance, and financing.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Medis is a pharmaceutical commercialization company that partners with innovative pharmaceutical and biotech companies to bring specialty pharmaceuticals, orphan drugs, advanced medical technologies, and consumer health products to Central & Eastern Europe and Greece. Through wholly-owned subsidiaries in 19 European countries, Medis delivers end-to-end commercialization services spanning regulatory affairs, pharmacovigilance, market access and pricing, medical affairs, marketing and sales, supply chain, quality assurance, and financing.

Product overview

Medis is a fully integrated pharmaceutical commercialization company operating as a platform with four distinct strategic business units. The core offering consists of Medis Therapeutics (specialty pharmaceuticals and orphan drugs across neurology, pulmonology, ophthalmology, oncology, rare diseases, immunology, endocrinology, gynecology, and hematology), Medis Consumer Health (OTC and consumer health products including digestive health, immunity, infant nutrition, pain relief, and personal care brands like Novalac and Defendyl/Imunoglukan), Medis Hospital Care (hospital medicines, diagnostics, surgery equipment, and medical technologies including simulation and robotics), and Medis Aesthetics (dermal fillers, neuromodulators, and non-invasive skin treatment devices). The company provides complete commercialization services including regulatory affairs, pharmacovigilance, quality assurance, marketing and sales, market access and pricing, medical affairs, and supply chain management. Medis operates an online store (Medisplus.si) for consumer OTC products in Slovenia, alongside its B2B pharmaceutical distribution operations across 19 European countries.

Differentiator

Problem solved

Functional benefit

Brands

• Medis Therapeutics: Business unit focusing on specialty pharmaceuticals in neurology, pulmonology, ophthalmology, oncology, rare diseases, immunology, endocrinology, gynecology, and hematology
• Medis Hospital Care
• Medis Consumer Health
• Medis Aesthetics
• Medis Awards
• Medisplus.si
• Novalac
• Defendyl/Imunoglukan

Products and services

• Medis Therapeutics Strategic business unit commercializing specialty pharmaceuticals and orphan drugs across multiple therapeutic areas (neurology, pulmonology, ophthalmology, oncology, rare diseases, immunology, endocrinology, gynecology, hematology) for innovative pharmaceutical and biotech partners across Central & Eastern Europe.
• Medis Consumer Health Strategic business unit commercializing consumer health and over-the-counter products across digestive health, immunity, hair/skin/nail health, infant nutrition, pain relief, oral health, and women's health through pharmacy and online channels in Central & Eastern Europe.
• Medis Hospital Care Strategic business unit commercializing hospital medicines, diagnostics, surgery products, hospital equipment, medical simulation, and robotization technologies for healthcare institutions through key account managers across Central & Eastern Europe.
• Medis Aesthetics Strategic business unit commercializing medical aesthetics products including dermal fillers, neuromodulators, non-invasive skin ultrasound devices, and non-invasive skin remodelling devices across Central & Eastern European markets.
• Medisplus.si Online Store Consumer-facing online pharmacy storefront operated by Medis in Slovenia where individuals can purchase over-the-counter products, dietary supplements, and consumer health items, with fulfillment through the pharmacy partner Lekarne Ljubljana.
• Full-service pharmaceutical commercialization End-to-end commercialization service offering for innovative pharmaceutical and biotech partners covering the entire product lifecycle across 19 European countries: regulatory affairs, pharmacovigilance, market access and pricing, medical affairs, marketing and sales, supply chain management, quality assurance, and financing.

Quantifiable outcome

• Medis provides quick reimbursements and fast sales uptake for its pharmaceutical and biotech partners.
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core and minor.

• WODA – World Orphan Drug AlliancecoreStrategic or Co-development PartnerMedis is a member of the World Orphan Drug Alliance (WODA), a global network of pharmaceutical companies and organizations focused on orphan drugs and rare diseases. This alliance enables Medis to access a broader network for orphan drug development and commercialization across its 19 European markets.
• Lekarne LjubljanaminorChannel Partner/ Reseller/ DistributorMedis partners with Lekarne Ljubljana (Ljubljana Pharmacies) for fulfillment of online orders placed through the Medisplus.si e-commerce store, with order delivery managed through this pharmacy chain partner.

Scale indicators6 records

Recent moves1 record

Expansion highlights6 records

Direct peers

• Ewopharma AG: Swiss pharma commercialization specialist focused on Central, Eastern, and Southeastern Europe — directly overlapping Medis's core business of bringing Western pharma and consumer health brands into CEE markets with full-service regulatory, market-access, and sales coverage.
• Midas Pharma GmbH: European pharma services and commercialization group offering full-service market entry, regulatory affairs, and distribution support across multiple European markets — closely aligned with Medis's value proposition of being an outsourced CEE commercialization platform.

Broad incumbents

• STADA Arzneimittel AG: Large European generics and specialty pharma player with established commercial infrastructure across CEE, including markets Medis covers; comparable as a multi-country CEE commercialization platform but at significantly greater scale and broader product ownership.
• Bayer (Pharmaceuticals CEE): Global pharma and consumer health major with dedicated CEE commercial operations; relevant as the type of large partner Medis serves, and as a benchmark for in-house commercialization scale that could compete with Medis.
• Krka, d. d. Slovenia-headquartered generic pharmaceutical manufacturer with deep CEE, Eastern, and Central European sales and marketing reach — a regional incumbent comparable in geography, therapeutic breadth, and field force model, though as a manufacturer-distributor rather than a service partner.
• Inizio (formerly Ashfield): Global pharma commercialization and advisory services group providing sales, medical, market access, and communications outsourcing; directly comparable to the strategic business unit Medis Therapeutics but operating across broader geographies and therapeutic areas.
• IQVIA Holdings: Global clinical, commercial, and real-world evidence services provider with CEE presence; comparable as a scale pharma commercialization services platform offering market access and sales force solutions to innovative manufacturers.

Regional players

• Neuraxpharm Arzneimittel GmbH: European specialty pharma company focused on CNS disorders with growing CEE footprint; comparable as a regional specialty pharma player commercializing through partner-led models in markets also served by Medis.

Others

• Galderma: Global dermatology and aesthetics pharmaceutical company, the type of manufacturer whose dermal fillers and neuromodulators are distributed in CEE through Medis Aesthetics — adjacent as a principal partner rather than a competitor.

Emerging players

• Lexpharma (or comparable CEE regulatory services): PharmaLex and similar European regulatory, pharmacovigilance, and market access consultancies serving CEE markets — emerging competitors in Medis's regulatory and pharmacovigilance service lines where pharma partners could route work to specialized providers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCBs-X_8G295ygHu05DsNZpQ
• Facebookfacebook.com/medis.si
• LinkedInlinkedin.com/company/medis_2
• Instagraminstagram.com/medis_health

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medis